TY  - JOUR
AU  - Gossec, Laure
AU  - Smolen, Josef S.
AU  - Ramiro, Sofia
AU  - Wit, Maarten de
AU  - Cutolo, Maurizio
AU  - Dougados, Maxime
AU  - Emery, Paul
AU  - Landewe, Robert
AU  - Oliver, Susan
AU  - Aletaha, Daniel
AU  - Betteridge, Neil
AU  - Braun, Juergen
AU  - Burmester, Gerd R. 
AU  - Canete, Juan D. 
AU  - Damjanov, Nemanja
AU  - FitzGerald, Oliver
AU  - Haglund, Emma
AU  - Helliwell, P.
AU  - Kvien, T. K.
AU  - Lories, Rik
AU  - Luger, Thomas
AU  - Maccarone, Mara
AU  - Marzo-Ortega, Helena
AU  - McGonagle, Dennis
AU  - McInnes, Iain B.
AU  - Olivieri, Ignazio
AU  - Pavelka, Karel
AU  - Schett, Georg
AU  - Sieper, Joachim
AU  - van den Bosch, F.
AU  - Veale, Douglas J.
AU  - Wollenhaupt, Juergen 
AU  - Zink, Angela
AU  - van der Heijde, D.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/955
AB  - Background Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. Results The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL) 12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. Conclusions These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.
T2  - Annals of the Rheumatic Diseases
T1  - European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
VL  - 75
IS  - 3
SP  - 499
EP  - 510
DO  - 10.1136/annrheumdis-2015-208337
ER  - 

@article{
author = "Gossec, Laure and Smolen, Josef S. and Ramiro, Sofia and Wit, Maarten de and Cutolo, Maurizio and Dougados, Maxime and Emery, Paul and Landewe, Robert and Oliver, Susan and Aletaha, Daniel and Betteridge, Neil and Braun, Juergen and Burmester, Gerd R.  and Canete, Juan D.  and Damjanov, Nemanja and FitzGerald, Oliver and Haglund, Emma and Helliwell, P. and Kvien, T. K. and Lories, Rik and Luger, Thomas and Maccarone, Mara and Marzo-Ortega, Helena and McGonagle, Dennis and McInnes, Iain B. and Olivieri, Ignazio and Pavelka, Karel and Schett, Georg and Sieper, Joachim and van den Bosch, F. and Veale, Douglas J. and Wollenhaupt, Juergen  and Zink, Angela and van der Heijde, D.",
year = "2016",
abstract = "Background Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. Methods A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. Results The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL) 12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. Conclusions These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.",
journal = "Annals of the Rheumatic Diseases",
title = "European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update",
volume = "75",
number = "3",
pages = "499-510",
doi = "10.1136/annrheumdis-2015-208337"
}

Gossec, L., Smolen, J. S., Ramiro, S., Wit, M. d., Cutolo, M., Dougados, M., Emery, P., Landewe, R., Oliver, S., Aletaha, D., Betteridge, N., Braun, J., Burmester, G. R., Canete, J. D., Damjanov, N., FitzGerald, O., Haglund, E., Helliwell, P., Kvien, T. K., Lories, R., Luger, T., Maccarone, M., Marzo-Ortega, H., McGonagle, D., McInnes, I. B., Olivieri, I., Pavelka, K., Schett, G., Sieper, J., van den Bosch, F., Veale, D. J., Wollenhaupt, J., Zink, A.,& van der Heijde, D.. (2016). European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. in Annals of the Rheumatic Diseases, 75(3), 499-510.
https://doi.org/10.1136/annrheumdis-2015-208337

Gossec L, Smolen JS, Ramiro S, Wit MD, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester GR, Canete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. in Annals of the Rheumatic Diseases. 2016;75(3):499-510.
doi:10.1136/annrheumdis-2015-208337 .

Gossec, Laure, Smolen, Josef S., Ramiro, Sofia, Wit, Maarten de, Cutolo, Maurizio, Dougados, Maxime, Emery, Paul, Landewe, Robert, Oliver, Susan, Aletaha, Daniel, Betteridge, Neil, Braun, Juergen, Burmester, Gerd R. , Canete, Juan D. , Damjanov, Nemanja, FitzGerald, Oliver, Haglund, Emma, Helliwell, P., Kvien, T. K., Lories, Rik, Luger, Thomas, Maccarone, Mara, Marzo-Ortega, Helena, McGonagle, Dennis, McInnes, Iain B., Olivieri, Ignazio, Pavelka, Karel, Schett, Georg, Sieper, Joachim, van den Bosch, F., Veale, Douglas J., Wollenhaupt, Juergen , Zink, Angela, van der Heijde, D., "European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update" in Annals of the Rheumatic Diseases, 75, no. 3 (2016):499-510,
https://doi.org/10.1136/annrheumdis-2015-208337 . .